Semaglutide and Heart Failure
It’s more than just weight loss:
Patients that were obese (BMI>30) with heart failure (well preserved ejection fraction) were evaluated over 52 weeks while treated with once weekly semaglutide or placebo. Decreases in the CRP level, systolic blood pressure, and NT-proBNP level were also greater in the semaglutide group than in the placebo, group (measures of inflammation and heart failure). Exercise tolerance was significantly improved in the CHF group. As expected, this group on semglutide vs placebo had significantly more weight loss. The number of cardiovascular serious adverse events reported was lower with semaglutide than with placebo.
Semaglutide appears to be effective in liver disease, perhaps Alzheimers